Back to top
more

Krystal Biotech (KRYS)

(Delayed Data from NSDQ)

$176.83 USD

176.83
1,549,911

+12.41 (7.55%)

Updated Jun 10, 2024 04:00 PM ET

After-Market: $176.80 -0.03 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KRYS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Krystal Biotech, Inc. [KRYS]

Reports for Purchase

Showing records 21 - 40 ( 68 total )

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

08/01/2022

Daily Note

Pages: 5

FDA Accepts KB407''s IND Application; Phase 1 Trial Prepped 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

06/22/2022

Daily Note

Pages: 4

VYJUVEK On Its Way to Potential Regulatory Approval With Solid Profile

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

05/10/2022

Company Report

Pages: 7

1Q22 Results; VYJUVEK on Track for Regulatory Submission While Pipeline Develops

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

04/19/2022

Industry Report

Pages: 7

Gene Therapy Conference; We Think Sentiment Starting to Improve

Provider: H.C. Wainwright & Co., Inc.

Analyst: BRANCHETTI E

Price: 12.50

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

03/28/2022

Company Report

Pages: 10

VYJUVEK Solidifies Its Profile At AAD Ahead of Regulatory Submission

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

03/22/2022

Company Report

Pages: 10

KB301 Moves Forward With Encouraging Efficacy and Safety; STAR-D Platform Validation Continues

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

02/28/2022

Company Report

Pages: 10

VYJUVEK On Its Way to Regulatory Submission While Pipeline Develops; Target Adjusted to $107

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

11/29/2021

Company Report

Pages: 11

B-VEC Wins; First Ever, Redosable, Topical Gene Therapy Could Soon Become Commercial Reality

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

11/08/2021

Company Report

Pages: 7

3Q21 Results; All Eyes on Imminent Pivotal B-VEC Data While Pipeline Develops

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

10/26/2021

Daily Note

Pages: 4

B-VEC Gets Closer to the Finish Line; Pivotal Data Are Imminent

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

10/19/2021

Company Report

Pages: 7

KB408 Enriches the Pulmonary Pipeline; B-VEC Pivotal Data Imminent

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for KRYS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

08/09/2021

Company Report

Pages: 6

2Q21 Results; B-VEC Steadily Approaching Prime Time While Pipeline Develops

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

08/03/2021

Daily Note

Pages: 4

KB301 Smooths Out Next Steps in Phase 1 Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

07/02/2021

Company Report

Pages: 7

No Rough Patch Here; KB105 Continues to Show Promise in ARCI

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

05/12/2021

Company Report

Pages: 7

First Look at Vectorized Antibodies at ASGCT; Growing Pipeline Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

05/10/2021

Company Report

Pages: 7

1Q21 Results; B-VEC Remains Primary Driver While Pipeline Develops Value-Creating Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

04/27/2021

Company Report

Pages: 5

GEM-3 Update Strengthens Statistical Plan for B-VEC Full Steam Ahead to 4Q21 Pivotal Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

04/19/2021

Daily Note

Pages: 5

Rare Lung Pipeline Gets a Nice Profile Boost; B-VEC Pivotal Data in 4Q21 Primary Driver

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

03/30/2021

Daily Note

Pages: 5

GEM-3 Completes Enrollment; B-VEC on Track to Deliver Pivotal Results in 4Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party